The team of Dr. Katerina Akassoglou at Gladstone Institutes and UCSF studied the gene signature of pathogenic innate immune cells in the CNS.
Calquence (Acalabrutinib), Astrazeneca’s bruton tyrosine kinase inhibitor, is thought to treat COVID-19 by suppressing lung macrophages.
Gilead and Galapagos NV announced the results of two phase 2 human trials evaluating filgotinib in adults with psoriatic arthritis.
Rights to the antibody candidate JTX-8064 have been transferred from Bristol-Myers Squibb back to Jounce Therapeutics effective June 3rd 2020.
TUM researchers have found that methylglyoxal underlies MDSC-mediated immunosuppression with implications for cancer diagnosis and treatment.
Interim analysis of the ZUMA-5 trial found that Yescarta showed efficacy for treating relapsed or refractory indolent non-hodgkin lymphoma.
Disulfiram, a drug approved by the FDA for treating alcohol addiction, has been found to antagonize inflammation and could treat key diseases .
Research by Dr. Arne Akbar and colleagues has shown that NK cell-like behavior of aging CD8+ T cells is linked to the expression of sestrins.
T-COVID is anticipated to provide clinical benefit to COVID-19 patients that are not yet hospitalized in the phase 1/2 clinical trial.